Your browser doesn't support javascript.
loading
Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia.
Madan, V; Shyamsunder, P; Han, L; Mayakonda, A; Nagata, Y; Sundaresan, J; Kanojia, D; Yoshida, K; Ganesan, S; Hattori, N; Fulton, N; Tan, K-T; Alpermann, T; Kuo, M-C; Rostami, S; Matthews, J; Sanada, M; Liu, L-Z; Shiraishi, Y; Miyano, S; Chendamarai, E; Hou, H-A; Malnassy, G; Ma, T; Garg, M; Ding, L-W; Sun, Q-Y; Chien, W; Ikezoe, T; Lill, M; Biondi, A; Larson, R A; Powell, B L; Lübbert, M; Chng, W J; Tien, H-F; Heuser, M; Ganser, A; Koren-Michowitz, M; Kornblau, S M; Kantarjian, H M; Nowak, D; Hofmann, W-K; Yang, H; Stock, W; Ghavamzadeh, A; Alimoghaddam, K; Haferlach, T; Ogawa, S; Shih, L-Y.
Afiliação
  • Madan V; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Shyamsunder P; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Han L; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Mayakonda A; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Nagata Y; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Sundaresan J; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kanojia D; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Yoshida K; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Ganesan S; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Hattori N; Department of Haematology, Christian Medical College, Vellore, India.
  • Fulton N; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Tan KT; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
  • Alpermann T; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Kuo MC; Munich Leukemia Laboratory (MLL), Munich, Germany.
  • Rostami S; Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan.
  • Matthews J; Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Sanada M; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu LZ; Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Shiraishi Y; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Miyano S; Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Chendamarai E; Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
  • Hou HA; Department of Haematology, Christian Medical College, Vellore, India.
  • Malnassy G; Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
  • Ma T; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
  • Garg M; Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany.
  • Ding LW; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Sun QY; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Chien W; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Ikezoe T; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Lill M; Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan.
  • Biondi A; Cedars-Sinai Medical Center, Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA, USA.
  • Larson RA; Paediatric Haematology-Oncology Department and 'Tettamanti' Research Centre, Milano-Bicocca University, 'Fondazione MBBM', San Gerardo Hospital, Monza, Italy.
  • Powell BL; Department of Medicine, University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
  • Lübbert M; Department of Internal Medicine, Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC, USA.
  • Chng WJ; Division of Hematology, Oncology and Stem Cell Transplantation, Department of Internal Medicine, University of Freiburg Medical Center, Freiburg, Germany.
  • Tien HF; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Heuser M; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Ganser A; Department of Hematology-Oncology, National University Cancer Institute of Singapore (NCIS), The National University Health System (NUHS), Singapore, Singapore.
  • Koren-Michowitz M; Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taipei, Taiwan.
  • Kornblau SM; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Kantarjian HM; Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
  • Nowak D; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Hofmann WK; Division of Hematology and Bone Marrow Transplantation, Sheba Medical Center, Tel Hashomer, Israel.
  • Yang H; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Stock W; Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ghavamzadeh A; Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany.
  • Alimoghaddam K; Department of Hematology and Oncology, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Mannheim, Germany.
  • Haferlach T; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
  • Ogawa S; Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
  • Shih LY; Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Leukemia ; 30(8): 1672-81, 2016 08.
Article em En | MEDLINE | ID: mdl-27063598
ABSTRACT
Acute promyelocytic leukemia (APL) is a subtype of myeloid leukemia characterized by differentiation block at the promyelocyte stage. Besides the presence of chromosomal rearrangement t(15;17), leading to the formation of PML-RARA (promyelocytic leukemia-retinoic acid receptor alpha) fusion, other genetic alterations have also been implicated in APL. Here, we performed comprehensive mutational analysis of primary and relapse APL to identify somatic alterations, which cooperate with PML-RARA in the pathogenesis of APL. We explored the mutational landscape using whole-exome (n=12) and subsequent targeted sequencing of 398 genes in 153 primary and 69 relapse APL. Both primary and relapse APL harbored an average of eight non-silent somatic mutations per exome. We observed recurrent alterations of FLT3, WT1, NRAS and KRAS in the newly diagnosed APL, whereas mutations in other genes commonly mutated in myeloid leukemia were rarely detected. The molecular signature of APL relapse was characterized by emergence of frequent mutations in PML and RARA genes. Our sequencing data also demonstrates incidence of loss-of-function mutations in previously unidentified genes, ARID1B and ARID1A, both of which encode for key components of the SWI/SNF complex. We show that knockdown of ARID1B in APL cell line, NB4, results in large-scale activation of gene expression and reduced in vitro differentiation potential.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Análise Mutacional de DNA / Leucemia Promielocítica Aguda Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Análise Mutacional de DNA / Leucemia Promielocítica Aguda Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article